MNG718
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.424
- KRAS_SIGNALING_DN+0.326
- ALLOGRAFT_REJECTION+0.315
- COAGULATION+0.309
- INTERFERON_GAMMA_RESPONSE+0.308
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.266
- APICAL_SURFACE+0.257
- IL6_JAK_STAT3_SIGNALING+0.253
- MYOGENESIS+0.232
- CHOLESTEROL_HOMEOSTASIS+0.215
Top 10 suppressed
- PROTEIN_SECRETION-0.565
- TGF_BETA_SIGNALING-0.473
- MITOTIC_SPINDLE-0.443
- ANDROGEN_RESPONSE-0.418
- UV_RESPONSE_DN-0.416
- G2M_CHECKPOINT-0.383
- MYC_TARGETS_V1-0.325
- PI3K_AKT_MTOR_SIGNALING-0.288
- HEDGEHOG_SIGNALING-0.286
- E2F_TARGETS-0.232
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD001516_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.889 |
| 2 | MDT-AP-0720 | Med | Medulloblastoma | 0.876 |
| 3 | TCGA-WT-AB41-01A-11R-A41B-07 | — | B | 0.871 |
| 4 | TCGA-LL-A5YN-01A-11R-A28M-07 | — | B | 0.858 |
| 5 | TCGA-E9-A5FK-01A-11R-A27Q-07 | — | B | 0.846 |
| 6 | ca188ec2-4185-4871-b71b-d024a37e5654 | — | — | 0.840 |
| 7 | SJEPD040_D.RNA-Seq | EPN | Supratentorial EPN | 0.837 |
| 8 | TCGA-A7-A56D-01A-11R-A27Q-07 | — | B | 0.835 |
| 9 | TCGA-OL-A66L-01A-12R-A31O-07 | — | B | 0.827 |
| 10 | TCGA-C8-A8HP-01A-11R-A36F-07 | — | D | 0.824 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.424 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.326 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.315 | Idelalisib | — uncovered |
| COAGULATION | 0.309 | Binimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.308 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.266 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.257 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.253 | Inavolisib | — uncovered |
| MYOGENESIS | 0.232 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.215 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.197 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.193 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.190 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.169 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.159 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.144 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.144 | Idelalisib | — uncovered |
| COMPLEMENT | 0.133 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.119 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.117 | Inavolisib | — uncovered |